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(EQ-5D), disease severity (DLQI), resource utilisation and productivity losses was 
collected from patient questionnaires. Patient characteristics and type of treatment 
were collected from patient records. Prescribed medications were collected from 
national drug registry data. RESULTS: During 12 months, 64% of the patients used 
only emollients and topical corticosteroids and 21% used systemic treatment (not 
biological). During part of or during the whole period 15% used biological treatment. 
Mean direct cost per patient related to in and out-patient care was estimated to a488, 
and indirect cost was a758. Cost for drugs was a1892 per patient and cost for light 
treatment was a930. QoL according to EQ-5D was 0.73 (SD 0.25), VAS 72.7 (SD 
20.6) and DLQI was 7.0 (SD 6.6) corresponding to “moderate effect on patient’s life”. 
CONCLUSIONS: Patients with more extensive psoriasis problems experienced lower 
QoL according to EQ-5D and higher discomfort and a larger effect on their lives 
according to DLQI. Direct and indirect costs increased with disease severity. Costs 
increased with the use of more potent drugs (biological and systemic drugs).
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OBJECTIVES: To describe costs of glaucoma treatment in Denmark by treatment 
sequence. METHODS: The analyses were based on registry data. A new or incident 
patient was deﬁned as a patient who did not use any medicine related to glaucoma 
for 6 months—that is, the study estimated the number of new patients in a 5.5 year 
period (from mid-2002 to 2007). New (incident) glaucoma patients (primary open-
angle glaucoma or ocular hypertension) were deﬁned via their “ﬁrst” use of prescribed 
medicine related to glaucoma (that is, via the ATC-codes) and the patients were identi-
ﬁed in the Danish Register of Medicinal Product Statistics for the years 2002–2007. 
Subsequently a cross sectional analysis for 2007 was performed including use of 
medicine related to glaucoma and use of services in the primary (ophthalmologists’ 
services) and secondary care services (relevant out-patient treatment and admissions 
—relevance deﬁned by a ICD10 code). Patients were categorized according to their 
number of treatment changes. RESULTS: Based on these data the yearly Danish inci-
dence was estimated to 1.2 per 1000 persons. The sex ratio (male/female) was 
44%/56% with a mean age of 68 and 71 years, respectively. Thirty-seven percent of 
the patients were in their ﬁrst treatment sequence (that is, no treatment changes), 21 
% were in their second, and 43 % of the patients had 3 or more treatment sequences. 
The number of treatment sequences inﬂuenced cost. The total costs of glaucoma 
(public payer perspective) were DKK 2200 (a300) per year for a patient in ﬁrst treat-
ment sequence whereas the corresponding costs for a patient with 3 or more treatment 
sequences were DKK 4600 (a610). Drug cost accounted for 62% of the total. CON-
CLUSIONS: Drugs represent the bulk of the costs of glaucoma and the costs increases 
with the number of treatment changes.
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OBJECTIVES: Use decision making tools to determine which of three alternatives—
Cochlear Implants, Hearing aids or no treatment- assure that a person, who suffers 
from Deep Neursosensorial Hypoacusia, will achieve the best cost-productivity rela-
tion for his or her life. METHODS: This study is based on a decision making analysis 
methodology which includes a description of the problem, a bibliographic review, a 
formulation of the problem, data analysis and incorporation, a mathematical model 
and results analysis. The problem is described as an alternatives issue concerning dif-
ferent treatments for Deep Neurosensorial Hypoacusia and a cost-productivity rela-
tion in order to evaluate each of the alternatives. This relation is measured as the NPV 
of the salary cash ﬂow that the patient expects to receive during his/her productive 
life as compared with the treatment and education costs. Actual data from the 
Cochlear Group of the Fundacion Santafe concerning audiology and language com-
prehension levels from patients using different treatments for deep deafness is analyzed 
in order to generate probability distributions and develop an inﬂuence diagram. 
Finally, a sensitivity analysis is conducted in order to verify the robustness of the 
solution obtained. RESULTS: As a result of the study was obtained that the cochlear 
implant provides a cost-productivity relation of COP$253,936,210 (US$123,871), 
Hearing aids: COP$ 138,307,940 (US$67,467) and not following any treatment: 
COP$107,510,318 (US$52,444). According to this assessment, the cochlear implant 
is the best treatment. CONCLUSIONS: According to the results, individuals who use 
a cochlear implant have a productivity of 1.5 times higher for individuals with hearing 
aids and almost 3 times higher than individuals who do not follow any treatment. 
This conﬁrms the excellent performance in terms of effectiveness and utility of the 
cochlear implant compared to hearing aids. The sensitivity analysis conducted showed 
that the cochlear implant is the best decision in a real scenario.
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OBJECTIVES: Non-compliance is frequently reported as a cause of treatment failure 
of oral antimicrobials. As the long-term injectable cefovecin eliminates non-compliance, 
the study objective was to investigate the impact of non-compliance on the costs and 
effectiveness of treatment of superﬁcial pyoderma, wounds and abscesses (SP-W-A), 
and deep pyoderma (DP) in dogs in Germany. METHODS: A Markov model, contain-
ing the health states “Worsening”, “Status quo”, “Improvement”, “Cure”, and 
“Relapse”, was adapted to Germany to calculate costs and beneﬁts (days without 
symptoms of SP-W-A or DP) over a 6-months (SP-WA) and 1-year (DP) period, for 
dogs on cefovecin versus amoxicillin/clavulanic acid (amoxi/clav). Efﬁcacy parameters 
were derived from clinical studies. For amoxi/clav, ﬁrst line treatment failure caused 
by non-compliance was estimated at 13.6% of all dogs, calculated from published 
literature. Cost data were derived from German ofﬁcial price and tariff lists (2009, 
dog owner’s perspective). All relevant input parameters were varied extensively in 
one-way and probabilistic sensitivity analyses. RESULTS: Cefovecin was more effec-
tive than amoxi/clav, with 161 versus 156 days without symptoms of SP-W-A and 
316 versus 307 days without symptoms of DP. Up to a bodyweight (b.w.) of 15 kg 
(SP-W-A) or 16 kg (DP), cefovecin was a dominant strategy, i.e. also cost-saving when 
considering total therapy expenditure (including anamnesis, diagnosis, treatment). In 
dogs of 25 kg b.w., total therapy costs for cefovecin were slightly increased versus 
comparator, a297.25 versus a272.72 (SP-W-A) and a 498.60 versus a477.75 (DP). 
Model outcomes were sensitive to changes of non-compliance data, but remained 
robust when varying other parameters. CONCLUSIONS: Considering non-compli-
ance with oral treatments as a cause of treatment failure, higher drug and administra-
tion costs of cefovecin became totally or partly offset by the increased incremental 
efﬁcacy resulting in less costs for supplementary treatments of relapses and failures.
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OBJECTIVES: Topical prostaglandin analogs combined with timolol demonstrate 
strong intra-ocular pressure lowering effect and are indicated in second line treatment. 
This study aims to estimate the 5-years cost effectiveness of Duotrav® and Xalacom® 
in second line glaucoma treatment in France from the perspective of the health care 
system. METHODS: A 5 year Markov model was built to populate the treatment of 
two cohorts of glaucoma patients. Time to treatment modiﬁcation, a key cost factor 
in real life, was estimated on the basis of an analysis of the UK GPRD database and 
a hazard-ratio (DuoTrav vs Xalacom) taken from a French observational study. Visual 
ﬁeld defect (VFD) occurrence rathes by treatment line were estimated from the litera-
ture. French standard costs were applied. Sensitivity analyses were carried out. 
RESULTS: Average times to treatment changes were 38.0 and 31.1 months for 
Duotrav and Xalacom, respectively. A total of 45.4% of the patients remained with 
their treatment at 5 years in the Duotrav cohort compared with 29.1% in the Xalacom 
group. The clinical beneﬁt of Duotrav was 0.06 less new VFDs on average per patient. 
The longer duration of treatment with Duotrav was associated with an extra costs of 
a144, an amount that was totally offset by a decrease in operating procedures (a98.7) 
and cost of rescue medications (a98.5). Other resources used (visits, exams..) were 
similar. Total costs were lower in the Duotrav cohort (a81.8) than in the Xalacom 
cohort. Sensitivity analyses conﬁrmed these ﬁndings. CONCLUSIONS: Treatment 
persistency is a key indicator of the effectiveness of chronic disease treatment in daily 
practice. The longer duration of treatment with Duotrav as compared with Xalacom 
lead to better glaucoma control, less VFD progression, and lower medical care costs. 
According to this analysis, DuoTrav economically dominates Xalacom.
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OBJECTIVES: Cefovecin, an injectable antimicrobial, maintains a therapeutic tissue 
concentration for approximately 14 days, and hence eliminates non-compliance 
reported with oral comparators. This study compared treatment costs and effectiveness 
of oral medication to cefovecin in resolving superﬁcial pyoderma, wounds, and 
abscesses (SP-W-A) in dogs. METHODS: A Markov model was developed to reﬂect 
treatment with cefovecin versus oral amoxicillin/clavulanic acid (amoxi/clav) over a 
six months period. The health states “Worsening”, “Status quo”, “Improvement”, 
“Cure”, and “Relapse” were included to reﬂect treatment costs and outcomes of ﬁrst, 
second and third line therapy protocols and account for treatment relapses. Effective-
ness parameters were derived from published clinical studies. For amoxi/clav, ﬁrst 
line treatment failure caused by non-compliance was estimated at 13.6% of all dogs 
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(calculated from published data). US cost data (2009, dog owner’s perspective) were 
estimated from public sources. Health outcomes were expressed in days without 
symptoms of SP-W-A. All relevant input parameters were varied extensively in one-
way and probabilistic sensitivity analyses, and therapeutic “break points” in costs and 
outcome were determined. RESULTS: Cefovecin was more effective than amoxi/clav 
(162 versus 158 days without symptoms of SP-W-A). Up to a bodyweight (b.w.) of 
31 kg, cefovecin was dominant compared to amoxi/clav ($376.74 versus $382.34 
respectively for dogs with b.w. of 25 kg) when considering total therapy expenditure 
(incl. anamnesis, diagnosis, treatments). In large dogs, cefovecin was more costly; 
however, total therapy costs were only 6% higher than amoxi/clav. Outcomes were 
sensitive to changes of non-compliance, but remained robust when varying other 
parameters. CONCLUSIONS: Considering non-compliance with oral treatments as a 
cause of treatment failure, cefovecin’s higher drug and administration costs are totally 
or substantially offset by its better effectiveness leading to reduced costs for supple-
mentary treatments of relapses and failures.
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OBJECTIVES: To assess the cost-effectiveness of ﬂexible dosing with etanercept 
compared with adalimumab or inﬂiximab treatment in patients with moderate to 
severe psoriasis. METHODS: An economic model was constructed to estimate the 
incremental cost per quality adjusted life year for each therapy compared with no 
systemic therapy (NST). Patients met UK criteria for biologic treatment, which require 
both a Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index 
(DLQI)   10 at baseline. Initial response rates were taken from registration studies 
for each agent: quality of life gain associated with response from patient level data in 
etanercept studies. Adalimumab and inﬂiximab were given continuously in line with 
product licenses. Etancercept can be used ﬂexibly, with some patients experiencing 
drug free intervals between courses of therapy: UK observational data found that 64% 
of etanercept users experience such intervals, with the remainder having continuous 
therapy. Response and withdrawal rates were taken from clinical studies, and extrapo-
lated to a time horizon of 10 years. Costs were estimated from a UK payer perspective 
including drugs, administration visits and hospital stay for treatment failures. Stochas-
tic analysis was undertaken to quantify uncertainty. RESULTS: The model estimated 
incremental cost-effectiveness ratios (ICER) of each therapy compared with NST to 
be: £12,600 (95% CI: £10,131, 14,066) for etanercept ﬂexible dosing; £17,975 
(£17,779, 31,106) for continuous adalimumab and £44,377 (£44,038, 73,815) for 
continuous inﬂiximab. The ICER for etanercept therapy was sensitive to the frequency 
and duration of drug free intervals in these patients but was below the ICER for con-
tinuous therapies. CONCLUSIONS: The model found ﬂexible dosing with etanercept 
to be more cost-effective than continuous therapy, as it allows control to be main-
tained at lower drug cost. This ﬁnding is consistent with a previous publication (Sitzo 
2008), but has now been conﬁrmed with drug utilisation data from UK practice.
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OBJECTIVES: This study aimed to estimate the cost per treatment failure avoided of 
topical preservative-free moxiﬂoxacin (MOXI) as compared with oﬂoxacin (OFLOX), 
marketed as preserved Traﬂoxal and preservative free Traﬂoxal E.D.O.in the treat-
ment of acute infectious conjunctivitis in The Netherlands (NL). METHODS: A survey 
amongst GPs and Ophthalmologists (OPH) collected health care resources(HCU) used 
to manage acute bacterial conjunctivitis. Cost of health care resourses were obtained 
from National databases; treatment failure rates were estimated from a meta-analysis 
of randomized controlled trials(RCT) investigating MOXI. A decision tree model in 
Treeage was populated to deﬁne the cost per treatment failure avoided using MOXI 
instead of OFLOX. OFLOX treatment failure rate was obtained from a trial directly 
comparing OFLOX with MOXI. Probabilistic sensitivity analysis was performed 
investigating the range of HCU used in clinical practice by different OPH and inves-
tigating the uncertainty around treatment failures reduction. RESULTS: The average 
estimated incremental cost per treatment failure avoided by a GP was a53.47 and 
a215a by an OPH (range a169.55a to a279.42). The treatment failure rate for MOXI 
was 2.9% [with 95% CI 1.4%,4.3%] versus 7.6% for OFLOX. The price for MOXI 
taken in the model was a14.04, the maximum reimbursement of current preservative 
free antibiotic treatments in NL. A weighted current average price of Traﬂoxal 
(110,943 units) and Traﬂoxal E.D.O.(15,554 units) was a3.74. With a failure rate less 
than half that for OFLOX, and assuming a willingness to pay (WTP) of 100a per 
treatment failure avoided (based on the WTP for avoiding allergic reactions), in 90% 
of the simulations MOXI is cost-effective. CONCLUSIONS: Use of topical moxiﬂoxa-
cin instead of oﬂoxacin avoids treatment failures. Moxiﬂoxacin, with a price of 14,04a 
is a cost-effective alternative to oﬂoxacin given a willingness to pay of a100 per treat-
ment failure avoided.
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OBJECTIVES: To determine the most cost-effective intravenous antibiotic treatment 
for complicated skin and skin-structure infections (cSSI) in public health care institu-
tions in Mexico. METHODS: A cost-effectiveness study with institutional perspective 
was conducted comparing the use of either i.v. Daptomycin (DAP), i.v. Vancomycin 
(VAN) or i.v. Linezolid (LIN) as ﬁrst-line and/or second-line antibiotic therapy. Data 
was collected from a systematic review which included the most recent published 
articles measuring clinical improvement, length of stay at hospital services and adverse 
events due to the use of any of three alternatives. A decision tree with Bayesian 
approach was designed to simulate the use of resources based on patient’s prognosis 
considering clinical success as the best health state, reached in either short hospital 
stay or long hospital stay, and a therapeutic failure of ﬁrst-line antibiotic therapy 
(DAP, VAN or LIN) which caused the use of a second-line antibiotic therapy (DAP 
or LIN depending on ﬁrst election). Costs calculation considered hospital stay, con-
comitant medication and selected antibiotic treatment. Results were evaluated with 
incremental analysis and one-way sensitivity analysis of the most uncertain variables. 
RESULTS: The use of DAP as ﬁrst-line therapy results in the lowest cost per clinical 
success (CS) (DAP: US$3,405.00/CS; VAN: US$3,550.00/CS; LIN: US$3,870.00/CS). 
In case of therapeutic failure of DAP, the use of LIN as second-line therapy resulted 
in the lowest total cost per clinical success (DAP-LIN: US$3,255.00/CS; VAN-DAP: 
US$3,310.00/CS; VAN-LIN: US$3,310.00/CS; LIN-DAP: US$3,423.00), reaching 
98% of CS. The sensitivity analysis varying clinical success rates of every evaluated 
alternative conﬁrmed the robustness of base study. CONCLUSIONS: Daptomycin is 
the most cost-effective alternative in the treatment of cSSI when used as ﬁrst-line 
antibiotic therapy since its use reduces the length of hospital stay reducing expenses 
of public health system budget in Mexico.
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TREATMENT IN ACTINIC KERATOSES
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OBJECTIVES: The purpose was to conduct a cost-effectiveness analysis (CEA) of 
imiquimod therapy compared to no treatment in patients with actinic keratoses (AKs) 
in Poland. METHODS: The analysis was based on a decision model regarding clinical 
effects of imiquimod therapy in comparison to placebo (vehicle cream), determined in 
randomized clinical trials. The population was deﬁned as adult patients with actinic 
keratoses, without hypertrophy and keratosis, with typical course (localisation on 
head skin), competent immune system of patient, when another treatment is contra-
indicated or inappropriate. Complete clearance was assessed as health outcome. Direct 
medical costs of the analyzed therapies were estimated from the perspective of both 
payers in Poland (National Health Fund and patient). Costs of medication and clinic 
visits were included. Time horizon of the analysis was 20 weeks. Treatment was 
assumed as once a day 3x/week, one or two 4-week cycles. Costs and effects were not 
discounted. RESULTS: Ratio of complete clearance was 0.620 for patients treated 
with imiquimod and 0.080 for patients taking placebo. Total costs of imiquimod 
therapy were estimated at 602.26 PLN, while costs of no treatment were 128.26 PLN. 
Incremental cost-effectiveness ratio (ICER) for the comparison of imiquimod versus 
placebo was calculated as 878 PLN per gained complete clearance. CONCLUSIONS: 
Imiquimod is more effective and more expensive than no treatment in patients with 
actinic keratoses. ICER value is below the acceptable threshold, therefore imiquimod 
therapy is considered as cost-effective treatment in Poland.
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OBJECTIVES: Glaucoma is associated with elevated intraocular pressure (IOP) which 
can develop nerve damage and loss of vision. Primary open angle glaucoma (POAG) 
or ocular hypertension (OH) patients should be treated with lowering IOP that is a 
major factor in preventing the progression of visual impairment related to glaucoma. 
Nowadays prostaglandin is recommended as ﬁrst-line treatment drug for reduction of 
elevated IOP. The main objective of this study is to evaluate the cost-effectiveness of 
taﬂuprost compared with latanoprost in POAG or OH patients in Korea. METHODS: 
A decision analytic model was developed from a societal perspective for one year to 
estimate clinical outcome, drug cost and glaucoma related cost. The model assumes 
pathways like following: successful treatment, switching to other drug, adding other 
drug, laser or surgery. Transition probabilities of successful treatment is deﬁned as 
the percentage of patients with elevated IOP achieving 20% reduction, and transition 
probabilities of switching is the percentage of patients who were withdrawn due to 
severe adverse events. IOP reduction rate and transition probabilities were obtained 
from published literatures searched in database. Resource utilizations and costs were 
calculated with Korean national health insurance data and clinical expert opinions. 
Sensitivity analyses were performed on crucial parameters. RESULTS: Taﬂuprost is 
